Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program
Authors:
Open Access
- 22 February 2019
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 29 (9) , 4678-4690
Abstract
Objectives The purpose of this study is to evaluate the predictive value of the amount of fibroglandular tissue (FGT) and background parenchymal enhancement (BPE), measured at baseline on breast MRI, for breast cancer development and risk of false-positive findings in women at increased risk for breast cancer. Methods Negative baseline MRI scans of 1533 women participating in a screening program for women at increased risk for breast cancer between January 1, 2003, and January 1, 2014, were selected. Automated tools based on deep learning were used to obtain quantitative measures of FGT and BPE. Logistic regression using forward selection was used to assess relationships between FGT, BPE, cancer detection, false-positive recall, and false-positive biopsy. Results Sixty cancers were detected in follow-up. FGT was only associated to short-term cancer risk; BPE was not associated with cancer risk. High FGT and BPE did lead to more false-positive recalls at baseline (OR 1.259, p = 0.050, and OR 1.475, p = 0.003) and to more frequent false-positive biopsies at baseline (OR 1.315, p = 0.049, and OR 1.807, p = 0.002), but were not predictive for false-positive findings in subsequent screening rounds. Conclusions FGT and BPE, measured on baseline MRI, are not predictive for overall breast cancer development in women at increased risk. High FGT and BPE lead to more false-positive findings at baseline. Key Points • Amount of fibroglandular tissue is only predictive for short-term breast cancer risk in women at increased risk. • Background parenchymal enhancement measured on baseline MRI is not predictive for breast cancer development in women at increased risk. • High amount of fibroglandular tissue and background parenchymal enhancement lead to more false-positive findings at baseline MRI.Keywords
Funding Information
- European Union?s Seventh Framework Programme for research, technological development and demonstration (601040)
This publication has 39 references indexed in Scilit:
- Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applicationsBreast Cancer Research and Treatment, 2017
- Dense and Nondense Mammographic Area and Risk of Breast Cancer by Age and Tumor CharacteristicsCancer Epidemiology, Biomarkers & Prevention, 2015
- Risk Factors and Tumor Characteristics of Interval Cancers by Mammographic DensityJournal of Clinical Oncology, 2015
- Digital mammographic density and breast cancer risk: a case–control study of six alternative density assessment methodsBreast Cancer Research, 2014
- Mammographic density and risk of breast cancer by age and tumor characteristicsBreast Cancer Research, 2013
- Mammographic Density, Estrogen Receptor Status and Other Breast Cancer Tumor CharacteristicsThe Breast Journal, 2010
- Breast MRI: guidelines from the European Society of Breast ImagingEuropean Radiology, 2008
- American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to MammographyCA: A Cancer Journal for Clinicians, 2007
- Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation CarriersCancer Research, 2006
- Application of Breast Cancer Risk Prediction Models in Clinical PracticeJournal of Clinical Oncology, 2003